Literature DB >> 17227254

[Allopurinol-induced chronic granulomatous interstitial nephritis].

J Almirall1, R Orellana, J C Martínez Ocaña, V Esteve, X Andreu.   

Abstract

Although drug induced interstitial nephritis is a relatively common cause of renal failure,granulomatous forms remain a rare condition. The development of a chronic granulomatous interstitial nephritis due to allopurinol is exceptional, only three cases have been described previously. We report on a patient who presented a granulomatous interstitial nephritis after 10 years of allopurinol administration (300 mg/day). At diagnosis, he had end stage renal disease and dialysis treatment was needed. Two months after drug withdrawal and on corticoid treatment a slow recovery of renal function was observed, allowing the interruption of dialysis. Two years after, the creatinine clearance is 23 ml/min,being dialysis free. We discuss the differential diagnosis of granulomatous interstitial nephritis and its rare association with allopurinol treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17227254

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  3 in total

1.  Potential Role of Allopurinol in Preventing Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial.

Authors:  Zahra Ghelich Khan; Azita Hajhossein Talasaz; Hamidreza Pourhosseini; Kianoush Hosseini; Mohammad Javad Alemzadeh Ansari; Arash Jalali
Journal:  Clin Drug Investig       Date:  2017-09       Impact factor: 2.859

2.  Granulomatous tubulointerstitial nephritis secondary to omeprazole.

Authors:  Quaid Nadri; Mohammed Mahdi Althaf
Journal:  BMJ Case Rep       Date:  2014-10-16

Review 3.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.